Loading…
Replimune Group, Inc. is projected to rise to $14.19 by 2027, a +27% move from its current price of $11.20. REPL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $10.03 | $11.20 | $12.52 | +0.04% |
| Aug 3 | $9.58 | $11.21 | $13.12 | +0.08% |
| Aug 4 | $9.25 | $11.21 | $13.59 | +0.12% |
| Aug 5 | $8.98 | $11.22 | $14.01 | +0.16% |
| Aug 6 | $8.75 | $11.22 | $14.39 | +0.20% |
| Aug 7 | $8.55 | $11.23 | $14.74 | +0.25% |
| Aug 8 | $8.37 | $11.23 | $15.07 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.37 | $11.23 | $15.07 | +0.29% |
| Week 2 | $7.43 | $11.26 | $17.08 | +0.58% |
| Week 3 | $6.79 | $11.30 | $18.80 | +0.86% |
| Week 4 | $6.29 | $11.33 | $20.40 | +1.15% |
| Week 5 | $5.89 | $11.36 | $21.93 | +1.44% |
| Week 6 | $5.54 | $11.39 | $23.42 | +1.74% |
| Week 7 | $5.25 | $11.43 | $24.88 | +2.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Replimune Group, Inc. is a clinical-stage biotechnology company in the Healthcare sector that focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. Its proprietary oncolytic immunotherapy product candidates are designed to activate the immune system against cancer.
Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL is a healthcare stock trading at $11.20 with a market cap of $941.09M. Its market position is reflected in a rank of 2467. The forecast suggests a path of price growth, with the average price in 2026 at $11.20, rising to $14.19 in 2027 and $19.74 in 2030.
Over the longer horizon, the forecast shows substantial upside, with 2040 average price of $98.45 and 2050 average price of $148.38.
A major floor 84.8% below — a decisive break under it would weaken the trend.
The nearest floor, 52.2% below — buyers have tended to step in here.
The nearest ceiling, 3.8% above — a clean break opens room to run.
A major ceiling 39.9% above — clearing it would confirm fresh momentum.
Key REPL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REPL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $7.20 | Buy | $8.18 | Buy |
| MA 10 | $8.84 | Buy | $8.54 | Buy |
| MA 20 | $9.69 | Buy | $9.14 | Buy |
| MA 50 | $9.26 | Buy | $8.85 | Buy |
| MA 100 | $7.13 | Buy | $8.12 | Buy |
| MA 200 | $7.83 | Buy | $7.86 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.23 | Neutral |
| Stoch RSI (14) | 94.75 | Sell |
| CCI (20) | 70.98 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.34 | Sell |
| ROC (12) | 15.70 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.24 | Sell |
| Awesome (5,34) | -2.87 | Sell |
| Ultimate (7,14,28) | 52.50 | Neutral |
| Momentum (10) | 0.97 | Buy |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 5.83 | Buy |
| ADX (14) | 27.02 | Buy |
| ATR (14) | 0.92 | Info |
Near term, sentiment is BULLISH with RSI(14) at 60. The price is above the 50-day simple moving average of $9.26 and above the 200-day simple moving average of $7.83. Key near-term levels include support at $5.35 and resistance at $11.63. The 30-day range spans from $5.38 to $23.31.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.70 | $11.20 | $14.25 | 0% | Neutral | |
| $10.33 | $14.19 | $21.05 | +27% | Bullish | |
| $10.06 | $14.68 | $23.25 | +31% | Bullish | |
| $10.54 | $16.23 | $26.98 | +45% | Bullish | |
| $12.24 | $19.74 | $34.19 | +76% | Bullish | |
| $13.74 | $23.17 | $41.55 | +107% | Bullish | |
| $20.64 | $36.31 | $67.14 | +224% | Bullish | |
| $23.83 | $43.67 | $83.01 | +290% | Bullish | |
| $21.71 | $41.38 | $80.67 | +270% | Bullish | |
| $23.04 | $45.64 | $91.06 | +308% | Bullish | |
| $44.30 | $98.45 | $215.92 | +779% | Bullish | |
| $66.77 | $148.38 | $341.27 | +12.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.70 | $11.20 | $13.61 | +0.00% |
| September 2026 | $9.37 | $11.41 | $14.50 | +1.85% |
| October 2026 | $9.42 | $11.63 | $15.07 | +1.92% |
| November 2026 | $8.78 | $10.96 | $14.44 | -5.71% |
| December 2026 | $8.46 | $10.67 | $14.25 | -2.68% |
Click any year to see its month-by-month REPL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Replimune Group, Inc.'s 2026 outlook centres on $11.20, within a $1.70 to $14.25 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, REPL could reach as high as $21.05, with a base case around $14.19 and support toward $10.33 — roughly +27% from $11.20. Buyers look set to stay in control over this stretch.
Expect REPL to range from $10.06 to $23.25 through 2028. The $14.68 average target implies a +31% move from current prices. That is up +4% on the projected 2027 average. Momentum favours further upside here.
The REPL price prediction for 2029 points to an average of $16.23 (low $10.54, high $26.98) — a potential gain of +45% on today's $11.20. Buyers look set to stay in control over this stretch.
In 2030, REPL is projected to trade between $12.24 and $34.19, averaging $19.74 — a potential gain of +76% from today's $11.20. That is up +22% on the projected 2029 average. Momentum favours further upside here.
Replimune Group, Inc.'s 2031 outlook centres on $23.17, within a $13.74 to $41.55 range. That is up +17% on the projected 2030 average. That marks a +107% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, REPL could reach as high as $67.14, with a base case around $36.31 and support toward $20.64 — roughly +224% from $11.20. Momentum favours further upside here.
Expect REPL to range from $23.83 to $83.01 through 2033. The $43.67 average target implies a +290% move from current prices. That is up +20% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The REPL price prediction for 2034 points to an average of $41.38 (low $21.71, high $80.67) — a potential gain of +270% on today's $11.20. Momentum favours further upside here.
In 2035, REPL is projected to trade between $23.04 and $91.06, averaging $45.64 — a potential gain of +308% from today's $11.20. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Replimune Group, Inc.'s 2040 outlook centres on $98.45, within a $44.30 to $215.92 range. That is up +116% on the projected 2035 average. That marks a +779% change versus current levels. Momentum favours further upside here.
By 2050, REPL could reach as high as $341.27, with a base case around $148.38 and support toward $66.77 — roughly +12.2x from $11.20. Buyers look set to stay in control over this stretch.
Investing $1,000 in REPL today (≈ 89.285714 REPL) could be worth
$13,248.13
+$12,248.13 (+1225%) by 2050 · US Dollar
Based on the average projected REPL price of $148.38 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REPLwould be worth at today's price.
$1,000 invested in REPL on Jul 31, 2025 (≈ 142.247506 REPL) would be worth
$1,593.17
+$593.17 (+59.3%) today · 1.59× · US Dollar
Based on a REPL entry price of $7.03 vs. today's $11.2.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.7 | $1,154.64 | +15.5% |
| 1 month ago | $11.22 | $998.22 | -0.2% |
| 3 months ago | $2.5 | $4,480 | +348.0% |
| 6 months ago | $6.97 | $1,605.73 | +60.6% |
| 1 year ago | $7.03 | $1,593.17 | +59.3% |
| All time (5.0y) ago | $33.35 | $335.83 | -66.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REPL forecast.
Our base-case forecast reaches $22.00 around 2031.
Implied market cap at $22.00: $1.85B
The multi-year forecast shows a rising trajectory. In 2026 the average price is $11.20, rising to $14.19 in 2027, $14.68 in 2028, $16.23 in 2029, and $19.74 in 2030. By 2031 the average is $23.17, 2032 is $36.31, 2033 is $43.67, 2034 is $41.38, and 2035 is $45.64. In 2040 the average is $98.45 and in 2050 the average is $148.38.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $19.74, with a min of $12.24 and a max of $34.19, ROI 76.3%, sentiment BULLISH.
The forecast shows bullish sentiment in 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035 and beyond, with rising average prices and ROI expanding from 0% in 2026 to 26.6% (2027), 31.1% (2028), 44.9% (2029), 76.3% (2030), 106.9% (2031), 224.2% (2032), 289.9% (2033), 269.5% (2034), 307.5% (2035), 779% (2040) and 1224.8% (2050). These are estimates.
Yes—the forecast's 2040 max is $215.92, which exceeds $200; the 2040 average is $98.45.
The 30-day range is from $5.38 to $23.31.
Current price is $11.20 and market cap is $941.09M.
Replimune Group, Inc. Community Discussion
0Share your Replimune Group, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.